T. Rowe Price Group (TROW) has announced that its assets under management (AUM) during the month ended November 30 declined 2.4% to $1.63 trillion. Following the news, shares of the Baltimore-based global investment manager dipped 1.6% to close at $196.17 on Friday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
T. Rowe Price’s client transfers from mutual funds to other portfolios, including trusts and separate accounts, were $1.1 billion in November.
AUM in Detail
November-end total assets in the U.S. mutual funds portfolio came in at $869 billion, down 2.6% from the prior month. Equity assets make up 64% of the portfolio, 26% are multi-assets, and the remaining 10% are fixed income and money market assets. Notably, equity assets fell 3.1% in November from the prior month.
Total assets from other investment portfolios were $759 billion, declining 2.6% from the previous month. Overall, equity and fixed income, including the money market, accounted for $518 billion or 68% of other investment portfolios, while multi-assets were $241 billion, or 32%.
T. Rowe Price recorded $384 billion in target date retirement portfolios, down 2.3% from the $393 billion reported in October. (See T. Rowe Price stock charts on TipRanks)
Wall Street’s Take
Following the AUM update, Jefferies (JEF) analyst Daniel Fannon maintained a Buy rating and a price target of $245 (24.9% upside potential) on the stock.
Overall, the stock has a Hold consensus rating based on 1 Buy, 5 Holds, and 1 Sell. The average T. Rowe Price price target of $219.29 implies 11.8% upside potential to current levels. Shares have increased 32.7% over the past year.
See Insiders’ Hot Stocks on TipRanks >>
Risk Analysis
According to the new TipRanks Risk Factors tool, T. Rowe Price stock is at risk mainly from three factors: Finance and Corporate, Legal and Regulatory, and Macro & Political, which contribute 32%, 20%, and 16%, respectively to the total 25 risks identified for the stock.
Related News:
Oracle Posts Upbeat Q2 Results; Shares Jump
Broadcom Jumps 6% on Upbeat Q4 Results, Dividend Hike
Pfizer-BioNTech COVID-19 Booster Gets FDA Approval for Ages 16 & Older